Dashboard
Manage Tickers

ARGXARGENX SE

Nasdaq argenx.com


$ 355.61 $ -3.87 (-1.08 %)    

Tuesday, 14-May-2024 13:28:35 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 443.79 $ -0.99 (-0.22 %)
DIA $ 394.00 $ -1.09 (-0.28 %)
SPY $ 521.00 $ -1.18 (-0.23 %)
TLT $ 90.72 $ 0.11 (0.12 %)
GLD $ 217.85 $ 0.00 (0 %)
$ 359.48
$ 355.65
$ 355.26 x 100
$ 356.47 x 105
$ 355.03 - $ 358.62
$ 327.73 - $ 550.76
343,985
na
21.28B
$ 0.82
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

jp-morgan-maintains-overweight-on-argenx-lowers-price-target-to-500
JP Morgan Maintains Overweight on argenx, ...
05/13/2024 14:25:10

JP Morgan analyst James Gordon maintains argenx (NASDAQ:ARGX) with a Overweight and lowers the price target from $560 to $500.

hc-wainwright--co-maintains-buy-on-argenx-lowers-price-target-to-448
HC Wainwright & Co. Maintains Buy on argen...
05/10/2024 19:33:19

HC Wainwright & Co. analyst Douglas Tsao maintains argenx (NASDAQ:ARGX) with a Buy and lowers the price target from $451...

breaking-down-argenx-12-analysts-share-their-views
Breaking Down argenx: 12 Analysts Share Th...
05/10/2024 19:01:01

jmp-securities-maintains-market-outperform-on-argenx-lowers-price-target-to-468
JMP Securities Maintains Market Outperform...
05/10/2024 16:43:05

JMP Securities analyst Jason Butler maintains argenx (NASDAQ:ARGX) with a Market Outperform and lowers the price target from...

why-duolingo-shares-are-trading-lower-by-around-18-here-are-other-stocks-moving-in-thursdays-mid-day-session
Why Duolingo Shares Are Trading Lower By A...
05/09/2024 17:57:05

why-applovin-shares-are-trading-higher-by-15-here-are-20-stocks-moving-premarket
Why AppLovin Shares Are Trading Higher By ...
05/09/2024 12:13:28

exact-sciences-reports-q1-loss-joins-beyond-meat-duolingo-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session
Exact Sciences Reports Q1 Loss, Joins Beyo...
05/09/2024 09:49:11

for-2024-argenx-expects-combined-research-and-development-and-selling-general-and-administrative-expenses-to-be-less-than-2b
For 2024 argenx Expects Combined Research ...
05/09/2024 06:08:33

FINANCIAL GUIDANCE Based on its current operating plans, argenx expects its combined Research and development and Selling, gen...

argenx-q1-2024-gaap-eps-052-beats-074-estimate-sales-398283m-miss-405776m-estimate
argenx Q1 2024 GAAP EPS $(0.52) Beats $(0....
05/09/2024 06:06:38

argenx (NASDAQ:ARGX) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.74) by 29....

the-analyst-verdict-argenx-in-the-eyes-of-12-experts
The Analyst Verdict: argenx In The Eyes Of...
04/18/2024 14:01:27

wedbush-reiterates-outperform-on-argenx-maintains-521-price-target
Wedbush Reiterates Outperform on argenx, M...
04/18/2024 13:21:52

Wedbush analyst David Nierengarten reiterates argenx (NASDAQ:ARGX) with a Outperform and maintains $521 price target.

hc-wainwright--co-reiterates-buy-on-argenx-maintains-451-price-target
HC Wainwright & Co. Reiterates Buy on arge...
04/18/2024 10:41:56

HC Wainwright & Co. analyst Douglas Tsao reiterates argenx (NASDAQ:ARGX) with a Buy and maintains $451 price target.

argenx-data-shows-evidence-that-vyvgart-and-vyvgart-hytrulo-deliver-transformative-results-for-patients-suffering-from-debilitating-autoimmune-diseases
argenx Data Shows Evidence That VYVGART An...
04/16/2024 07:18:27

ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstr...

cartesian-therapeutics-rare-disease-candidate-shows-long-lasting-benefit-over-argenxs-vyvgart-analyst-initiates-with-buy
Cartesian Therapeutics' Rare Disease Candi...
04/10/2024 18:34:58

Cartesian Therapeutics' autoimmune disease treatment with re-dosable mRNA CAR-Ts. Learn about Descartes-08, a promising ant...

hc-wainwright--co-maintains-buy-on-argenx-maintains-451-price-target
HC Wainwright & Co. Maintains Buy on argen...
03/27/2024 14:49:47

HC Wainwright & Co. analyst Douglas Tsao maintains argenx (NASDAQ:ARGX) with a Buy and maintains $451 price target.

argenx-announces-plan-to-continue-the-development-of-efgartigimod-primary-sjogrens-disease
argenx Announces Plan To Continue The Deve...
03/27/2024 07:06:00

RHO study supports proof-of-concept in primary Sjogren's disease Decision informed by favorable safety profile and consi...

key-takeaways-from-argenx-analyst-ratings
Key Takeaways From argenx Analyst Ratings
03/26/2024 19:01:17

tesla-to-120-here-are-10-top-analyst-forecasts-for-tuesday
Tesla To $120? Here Are 10 Top Analyst For...
03/26/2024 12:30:05

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

scotiabank-maintains-sector-perform-on-argenx-raises-price-target-to-408
Scotiabank Maintains Sector Perform on arg...
03/26/2024 11:24:44

Scotiabank analyst George Farmer maintains argenx (NASDAQ:ARGX) with a Sector Perform and raises the price target from $402 ...

argenx-receives-approval-of-vyvgart-in-japan-for-adults-with-primary-immune-thrombocytopenia
argenx Receives Approval Of VYVGART In Jap...
03/26/2024 07:15:42

VYVGART® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP) Regulatory dec...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION